查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081841

放射性藥物市場：2026-2032年全球市場預測（按產品類型、產品劑型、放射性同位素類型、生產技術、分子類型、給藥途徑、劑量形式、治療方法、應用和最終用戶分類）

Radiopharmaceuticals Market by Product Type, Product Format, Radioisotope Type, Production Technology, Molecule Type, Route Of Administration, Dose Presentation, Therapeutic Approach, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，放射性藥物市場規模將成長至 91.9 億美元，複合年成長率為 6.69%。

主要市場統計數據
基準年 2025 58.4億美元
預計年份：2026年 62億美元
預測年份：2032年 91.9億美元
複合年成長率 (%) 6.69%

放射性藥物市場概覽

放射性藥物正從核醫這一專業領域轉向高附加價值的精準癌症治療和影像領域。這些放射性藥物透過將生物活性標靶分子與醫用放射性同位素結合，能夠實現疾病可視化、闡明腫瘤生物學特徵，並將輻射靶向輸送至病變組織，同時最大限度地減少對周圍健康細胞的輻射暴露。

放射性藥物產業的變革性變化

分子影像、標靶放射性核素治療和個人化醫療的融合正在重塑放射性藥物的市場結構。診斷和治療正透過「治療診斷學」模式日益緊密地聯繫在一起，該模式能夠識別合格的患者、量化疾病負擔，並利用相同的生物標的進行精準放射治療。

人工智慧（AI）的累積影響

人工智慧 (AI) 在放射性藥物的整個生命週期中累積創造價值，從目標發現和配體最佳化到影像重建、病灶檢測、劑量測定和生產品管。 AI 驅動的影像分析有助於提高 PET 和 SPECT 影像解讀的一致性，減少解讀者之間的差異，並使用標準化參數來量化治療反應。

關鍵區域洞察

由於PET和SPECT技術的廣泛應用、大規模的腫瘤醫療基礎設施、FDA監管的產品核可流程以及對鎦-177和錒-225供應鏈的持續投入，北美仍然是放射性藥物領域最先進的地區之一。美國憑藉其學術核醫學專長、商業性放射性藥物網路以及對前列腺癌影像和治療的強勁需求，在該領域擁有尤為強大的影響力。另一方面，加拿大則擁有強大的核子研究能力和對腫瘤診斷的醫療需求。

主要群體分析

在東協，醫院核子醫學投資、PET/CT技術的引進以及癌症治療的現代化都在穩步推進。然而，由於新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國的基礎設施成熟度存在顯著差異，區域間夥伴關係、人力資源開發以及同位素物流系統對於改善整個區域放射性藥物的可及性至關重要。

主要國家概況

美國憑藉FDA的核准、高密度的臨床試驗、放射性藥物藥局網路以及PSMA-PET影像和鎦-177療法的快速應用，引領先進放射性藥物的商業化過程。加拿大憑藉其核醫學研究能力和對腫瘤成像的醫療需求，為市場發展提供了支持；而墨西哥則在其不斷發展的公立和私立醫療保健體系的支持下，擴大了主要都市地區的診斷服務覆蓋範圍。

為行業領導者提供的實用建議

產業供應商應優先考慮同位素的穩定供應，並透過核子反應爐、迴旋加速器、產生器和核子反應爐等多種供應管道實現供應多元化。由於同位素半衰期短，且運輸限制和反應器維護計劃可能直接影響患者治療的連續性，因此制定穩健的籌資策略至關重要。

調查方法

本執行摘要採用系統的二手資料研究途徑編寫，重點關注來自監管機構、世界衛生組織、科學文獻、臨床實驗室註冊機構、核醫學權威機構以及公開的行業資訊的檢驗公開資訊。資訊來源包括美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 的產品資訊、國際原子能總署 (IAEA) 的核子醫學相關資料、世衛組織癌症負擔參考資料、同行評審期刊以及經認可的輻射防護指南。

結論

隨著精準成像和標靶放射性核素治療在現代腫瘤學和專業診斷中日益重要，放射性藥物正處於關鍵發展階段。推動這一市場發展的因素包括臨床證據、監管政策的進步、生產製造投入的增加以及對個人化醫療日益成長的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：放射性藥物市場：依產品類型分類

  • 診斷
  • 治療部分
  • 治療診斷對

第8章：放射性藥物市場：依產品形式分類

  • 即用型產品
  • 冷療包
  • 放射性標記前驅物

第9章：放射性藥物市場：依放射性同位素類型分類

  • 氟-18
  • 鎵-68
  • 碘-131
  • 鎦-177
  • Technetium-99m

第10章：放射性藥物市場：依生產技術分類

  • 自動合成模組
  • 迴旋加速器系統
  • 生成器方法
  • 核子反應爐方法

第11章：放射性藥物市場：依分子類型分類

  • 低分子化合物
  • 胜肽
  • 單株抗體
  • 顆粒和微球

第12章：放射性藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 動脈內部

第13章：放射性藥物市場：以劑型分類

  • 單一劑量
  • 多次給藥

第14章 放射性藥物市場：依治療方法分類

  • 放射性配體療法
  • 放射免疫療法
  • 放射性栓塞療法
  • 骨標靶治療

第15章：放射性藥物市場：依應用領域分類

  • 循環系統
  • 內分泌學
  • 神經病學
  • 腫瘤學

第16章：放射性藥物市場：依最終用戶分類

  • 診所
  • 診斷中心
  • 醫院

第17章：放射性藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第18章：放射性藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章：放射性藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第21章 公司簡介

  • 3B Pharmaceuticals GmbH
  • Abdera Therapeutics Inc.
  • Actineer Inc.
  • Actinium Pharmaceuticals, Inc.
  • Actithera Ltd.
  • AdvanCell Pty Ltd
  • Aktis Oncology, Inc.
  • Alliance Holdings Medical Limited
  • Alpha Tau Medical Ltd.
  • Alpha-9 Oncology Inc.
  • AmbioPharm, Inc.
  • ARTBIO, Inc.
  • Bayer AG
  • Bracco Group
  • BWX Technologies. Inc.
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals
  • Curium Pharma
  • Eckert & Ziegler Group
  • Eczacibasi-Monrol Nuclear Products Co.
  • GE HealthCare Technologies, Inc.
  • Global Medical Solutions
  • International Isotopes, Inc.
  • IsoTherapeutics Group, LLC
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Pharma Holdings Inc.
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt PLC
  • Northstar Medical Technologies LLC
  • Novartis AG
  • NTP Radioisotopes SOC Ltd.
  • Siemens Healthineers AG
  • Sinotau Pharmaceutical Group
Product Code: MRR-4308E1C887A3

The Radiopharmaceuticals Market is projected to grow by USD 9.19 billion at a CAGR of 6.69% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.84 billion
Estimated Year [2026] USD 6.20 billion
Forecast Year [2032] USD 9.19 billion
CAGR (%) 6.69%

Radiopharmaceuticals Market Introduction

Radiopharmaceuticals are moving from a specialized nuclear medicine category into a high-value precision oncology and diagnostic imaging field. These radioactive compounds combine a biologically active targeting molecule with a medical radioisotope to visualize disease, characterize tumor biology, or deliver targeted radiation to diseased tissue while limiting exposure to surrounding healthy cells.

Market momentum is supported by the clinical adoption of PET and SPECT imaging, the expanding use of theranostics, and regulatory approvals for targeted radioligand therapies, including lutetium-177-based prostate-specific membrane antigen (PSMA) therapy. Demand is also tied to rising cancer prevalence, aging populations, and the need for earlier, more accurate diagnosis in oncology, cardiology, neurology, and endocrinology.

For industry vendors, the radiopharmaceuticals market is defined by scientific innovation and operational complexity. Short isotope half-lives, stringent radiation safety rules, GMP manufacturing requirements, and specialized logistics create high barriers to entry, while strong clinical utility and growing investment in radiopharmaceutical manufacturing capacity create durable opportunities.

Transformative Shifts in the Radiopharmaceuticals Landscape

The radiopharmaceuticals landscape is being reshaped by the convergence of molecular imaging, targeted radionuclide therapy, and personalized medicine. Diagnostics and therapeutics are increasingly linked through the theranostic model, where the same biological target can be used to identify eligible patients, quantify disease burden, and deliver precision radiation therapy.

A major shift is the transition from conventional imaging isotopes and broad-use nuclear medicine procedures toward highly specific oncology agents. Gallium-68, fluorine-18, technetium-99m, iodine-131, lutetium-177, radium-223, and emerging alpha emitters such as actinium-225 are central to product development strategies, each with distinct implications for production, distribution, radiation safety, and clinical workflow.

The competitive landscape is also changing as pharmaceutical developers, isotope producers, contract manufacturers, academic centers, and hospital radiopharmacies form integrated ecosystems. Securing radioisotope supply, validating decentralized or regional manufacturing models, and building physician confidence through evidence-based clinical outcomes are now decisive differentiators.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding cumulative value across the radiopharmaceutical lifecycle, from target discovery and ligand optimization to image reconstruction, lesion detection, dosimetry, and manufacturing quality control. AI-enabled imaging analytics can support more consistent PET and SPECT interpretation, reduce inter-reader variability, and help quantify treatment response using standardized parameters.

In radiopharmaceutical therapy, AI is especially relevant to patient-specific dosimetry. By integrating imaging data, organ segmentation, pharmacokinetic models, and clinical variables, AI tools can help estimate absorbed dose more efficiently and support safer, more individualized treatment planning. This is important as radioligand therapy moves beyond single fixed-dose approaches toward adaptive protocols.

AI also strengthens operational performance. Predictive models can improve isotope production planning, cold-chain and radiation-compliant logistics, batch release scheduling, and equipment maintenance. However, adoption depends on validated algorithms, explainable outputs, cybersecurity controls, and compliance with FDA, EMA, and other regulatory expectations for software used in clinical decision support and regulated manufacturing.

Key Regional Insights

North America remains one of the most advanced radiopharmaceutical regions due to broad PET and SPECT adoption, a large oncology care base, FDA-regulated product pathways, and expanding investment in lutetium-177 and actinium-225 supply chains. The United States is particularly influential because it combines academic nuclear medicine expertise, commercial radiopharmacy networks, and strong demand for prostate cancer imaging and therapy, while Canada contributes nuclear research capabilities and healthcare demand for oncology diagnostics.

Europe benefits from mature nuclear medicine infrastructure, EMA oversight, and strong clinical research networks across Germany, France, Italy, Spain, the United Kingdom, and Nordic countries. The region is advancing theranostics through university hospitals and cross-border clinical collaboration, while also addressing isotope security, radiation protection, and harmonization of radiopharmaceutical preparation standards.

Asia-Pacific is gaining strategic importance as China, Japan, India, South Korea, and Australia expand cancer diagnostics, cyclotron capacity, and radiopharmaceutical research. Japan has long-standing nuclear medicine capabilities, Australia has recognized isotope production strengths, China is scaling oncology infrastructure, and India is improving access through public and private nuclear medicine investments.

Latin America, led by Brazil and Mexico, presents growing demand for oncology and cardiology imaging but faces uneven access to PET infrastructure and specialized radiopharmacies. The Middle East, particularly GCC health systems, is investing in advanced oncology centers and nuclear medicine services, while Africa shows long-term potential as IAEA-supported capacity building improves training, equipment access, and regulatory readiness for safe radiopharmaceutical use.

Key Group Insights

ASEAN markets are progressing through investments in hospital-based nuclear medicine, PET/CT installation, and cancer care modernization. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines vary significantly in infrastructure maturity, making regional partnerships, workforce training, and isotope logistics essential for improving radiopharmaceutical access across the bloc.

The GCC is becoming a high-investment cluster for advanced diagnostics and oncology treatment, supported by national health transformation programs in Saudi Arabia, the United Arab Emirates, Qatar, and neighboring states. Demand is supported by premium hospital development, medical tourism ambitions, and the need to localize complex specialty care, including PET imaging and targeted radionuclide therapy.

The European Union provides one of the most structured regulatory and research environments for radiopharmaceuticals. EU funding frameworks, cross-border clinical trials, and coordinated radiation protection standards support innovation, while the region continues to prioritize resilient isotope supply and GMP-compliant radiopharmacy practices.

BRICS countries represent a major development platform because Brazil, Russia, India, China, and South Africa combine large patient populations with expanding nuclear medicine needs and domestic healthcare modernization priorities. G7 markets continue to drive premium innovation, regulatory precedent, and commercialization of advanced radioligand therapies. NATO countries, many of which overlap with G7 and EU members, are also focused on nuclear security, isotope resilience, and protection of critical medical supply chains.

Key Country Insights

The United States leads commercialization of advanced radiopharmaceuticals through FDA approvals, clinical trial density, radiopharmacy networks, and rapid adoption of PSMA PET imaging and lutetium-177 therapies. Canada supports the market through nuclear research capabilities and healthcare demand for oncology imaging, while Mexico is expanding diagnostic access in major urban centers supported by growing private and public healthcare capacity.

Brazil is the largest Latin American opportunity due to its hospital base and oncology demand, although isotope distribution, reimbursement, and infrastructure concentration remain key constraints. The United Kingdom maintains strong academic and NHS-linked nuclear medicine capabilities, while Germany is a European leader in theranostics, radiochemistry, and clinical adoption. France benefits from advanced oncology research and radiopharmaceutical manufacturing expertise, and Italy and Spain continue to expand nuclear medicine access within public healthcare systems.

Russia has technical nuclear capabilities and domestic demand, though geopolitical constraints can affect collaboration and supply chains. China is rapidly scaling PET/CT access, oncology infrastructure, and domestic radiopharmaceutical development. India offers long-term growth through cancer burden, cost-sensitive care models, and expanding nuclear medicine capacity. Japan remains important for imaging innovation and an aging population, Australia contributes isotope production and research depth, and South Korea is advancing precision medicine through strong hospital systems and biotechnology investment.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize secure isotope access by diversifying reactor, cyclotron, generator, and accelerator-based supply options. A resilient sourcing strategy is essential because short half-lives, transport restrictions, and reactor maintenance schedules can directly affect patient treatment continuity.

Companies should invest in theranostic platforms that connect diagnostic imaging agents with matched therapeutic radiopharmaceuticals. This approach improves patient selection, strengthens clinical value propositions, and supports differentiated reimbursement discussions based on measurable outcomes.

Manufacturers and healthcare providers should expand GMP-compliant regional production, automated synthesis, digital batch documentation, and radiation-safe logistics. Vendors should also develop AI-enabled image quantification and dosimetry capabilities, but only through validated, auditable systems aligned with clinical and regulatory requirements.

Commercial success will depend on multidisciplinary education for oncologists, nuclear medicine physicians, radiologists, medical physicists, pharmacists, and payers. Building evidence around survival, quality of life, workflow efficiency, and total cost of care will be critical to accelerating adoption.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public information from regulatory agencies, international health organizations, scientific literature, clinical trial registries, nuclear medicine authorities, and publicly available industry disclosures. Sources considered include FDA and EMA product information, IAEA nuclear medicine resources, WHO cancer burden references, peer-reviewed journals, and recognized radiation protection guidance.

The methodology emphasizes triangulation across clinical, regulatory, technological, and supply chain indicators. Key themes were evaluated by reviewing approved radiopharmaceutical products, isotope production routes, imaging and therapy adoption patterns, regional healthcare infrastructure, and the role of AI in nuclear medicine workflows.

Insights are presented qualitatively and avoid unsupported numerical claims. The analysis focuses on evidence-based market direction, operational constraints, regional differences, and strategic implications relevant to stakeholders across pharmaceutical development, isotope production, radiopharmacy, diagnostics, oncology care, and healthcare investment.

Conclusion

Radiopharmaceuticals are entering a defining phase as precision imaging and targeted radionuclide therapy become central to modern oncology and specialized diagnostics. The market is supported by clinical evidence, regulatory progress, expanding manufacturing investment, and growing demand for personalized treatment pathways.

The strongest opportunities will favor organizations that can combine scientific differentiation with operational reliability. Isotope security, GMP execution, AI-enabled workflow optimization, physician education, and payer evidence will determine which organizations convert innovation into scalable clinical adoption.

As healthcare systems seek earlier diagnosis and more targeted treatment, radiopharmaceuticals are positioned to become a critical pillar of precision medicine. Stakeholders that act now to build resilient platforms, compliant infrastructure, and outcome-driven partnerships will be best placed to lead the next stage of market development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Radiopharmaceuticals Market, by Product Type

  • 7.1. Diagnostic
  • 7.2. Therapeutic
  • 7.3. Theranostic Pairs

8. Radiopharmaceuticals Market, by Product Format

  • 8.1. Ready-To-Use Products
  • 8.2. Cold Kits
  • 8.3. Radiolabeling Precursors

9. Radiopharmaceuticals Market, by Radioisotope Type

  • 9.1. Fluorine-18
  • 9.2. Gallium-68
  • 9.3. Iodine-131
  • 9.4. Lutetium-177
  • 9.5. Technetium-99m

10. Radiopharmaceuticals Market, by Production Technology

  • 10.1. Automated Synthesis Modules
  • 10.2. Cyclotron Based
  • 10.3. Generator Based
  • 10.4. Reactor Based

11. Radiopharmaceuticals Market, by Molecule Type

  • 11.1. Small Molecules
  • 11.2. Peptides
  • 11.3. Monoclonal Antibodies
  • 11.4. Particles And Microspheres

12. Radiopharmaceuticals Market, by Route Of Administration

  • 12.1. Intravenous
  • 12.2. Oral
  • 12.3. Intra-Arterial

13. Radiopharmaceuticals Market, by Dose Presentation

  • 13.1. Unit Dose
  • 13.2. Multi-Dose

14. Radiopharmaceuticals Market, by Therapeutic Approach

  • 14.1. Radioligand Therapy
  • 14.2. Radioimmunotherapy
  • 14.3. Radioembolization
  • 14.4. Bone-Targeted Therapy

15. Radiopharmaceuticals Market, by Application

  • 15.1. Cardiology
  • 15.2. Endocrinology
  • 15.3. Neurology
  • 15.4. Oncology

16. Radiopharmaceuticals Market, by End User

  • 16.1. Clinics
  • 16.2. Diagnostic Centres
  • 16.3. Hospitals

17. Radiopharmaceuticals Market, by Region

  • 17.1. Asia-Pacific
  • 17.2. North America
  • 17.3. Latin America
  • 17.4. Europe
  • 17.5. Middle East
  • 17.6. Africa

18. Radiopharmaceuticals Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Radiopharmaceuticals Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025

21. Company Profiles

  • 21.1. 3B Pharmaceuticals GmbH
  • 21.2. Abdera Therapeutics Inc.
  • 21.3. Actineer Inc.
  • 21.4. Actinium Pharmaceuticals, Inc.
  • 21.5. Actithera Ltd.
  • 21.6. AdvanCell Pty Ltd
  • 21.7. Aktis Oncology, Inc.
  • 21.8. Alliance Holdings Medical Limited
  • 21.9. Alpha Tau Medical Ltd.
  • 21.10. Alpha-9 Oncology Inc.
  • 21.11. AmbioPharm, Inc.
  • 21.12. ARTBIO, Inc.
  • 21.13. Bayer AG
  • 21.14. Bracco Group
  • 21.15. BWX Technologies. Inc.
  • 21.16. Cardinal Health, Inc.
  • 21.17. Clarity Pharmaceuticals
  • 21.18. Curium Pharma
  • 21.19. Eckert & Ziegler Group
  • 21.20. Eczacibasi-Monrol Nuclear Products Co.
  • 21.21. GE HealthCare Technologies, Inc.
  • 21.22. Global Medical Solutions
  • 21.23. International Isotopes, Inc.
  • 21.24. IsoTherapeutics Group, LLC
  • 21.25. Isotopia Molecular Imaging Ltd.
  • 21.26. Jubilant Pharma Holdings Inc.
  • 21.27. Lantheus Medical Imaging, Inc.
  • 21.28. Mallinckrodt PLC
  • 21.29. Northstar Medical Technologies LLC
  • 21.30. Novartis AG
  • 21.31. NTP Radioisotopes SOC Ltd.
  • 21.32. Siemens Healthineers AG
  • 21.33. Sinotau Pharmaceutical Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOPHARMACEUTICALS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RADIOPHARMACEUTICALS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICALS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICALS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 31. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 33. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THERANOSTIC PAIRS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THERANOSTIC PAIRS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THERANOSTIC PAIRS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL READY-TO-USE PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL READY-TO-USE PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL READY-TO-USE PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLD KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLD KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLD KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOLABELING PRECURSORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIOLABELING PRECURSORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOLABELING PRECURSORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FLUORINE-18 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FLUORINE-18 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FLUORINE-18 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GALLIUM-68 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GALLIUM-68 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GALLIUM-68 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IODINE-131 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IODINE-131 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IODINE-131 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LUTETIUM-177 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUTETIUM-177 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TECHNETIUM-99M MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TECHNETIUM-99M MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATED SYNTHESIS MODULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATED SYNTHESIS MODULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATED SYNTHESIS MODULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CYCLOTRON BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYCLOTRON BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYCLOTRON BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENERATOR BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENERATOR BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENERATOR BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL REACTOR BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL REACTOR BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL REACTOR BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PARTICLES AND MICROSPHERES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PARTICLES AND MICROSPHERES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PARTICLES AND MICROSPHERES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRA-ARTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRA-ARTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRA-ARTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL UNIT DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL UNIT DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL UNIT DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MULTI-DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTI-DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MULTI-DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RADIOLIGAND THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RADIOLIGAND THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RADIOLIGAND THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RADIOIMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RADIOIMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RADIOIMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RADIOEMBOLIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RADIOEMBOLIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RADIOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BONE-TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BONE-TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BONE-TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIAGNOSTIC CENTRES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DIAGNOSTIC CENTRES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIAGNOSTIC CENTRES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 199. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 205. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. G7 RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 232. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 238. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. NATO RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 243. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 248. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 249. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 332. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 336. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. ITALY RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 343. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 345. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 347. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 348. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 349. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 350. ITALY RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. SPAIN RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 352. SPAIN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 353. SPAIN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT FORMAT, 2018-2032 (USD MILLION)
  • TABLE 354. SPAIN RADIOPHARMACEUTICALS MARKET SIZE, BY RADIOISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. SPAIN RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 356. SPAIN RADIOPHARMACEUTICALS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. SPAIN RADIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 358. SPAIN RADIOPHARMACEUTICALS MARKET SIZE, BY DOSE PRESENTATION, 2018-2032 (USD MILLION)
  • TABLE 359. SPAIN RADIOPHARMACEUTICAL